Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells

Despite the benefits of imatinib for treating gastrointestinal stromal tumors (GIST), the prognosis for high risk GIST and imatinib-resistant (IR) GIST remains poor. The mechanisms of imatinib resistance have not yet been fully clarified. The aim of the study was to establish imatinib-resistant cell...

Full description

Bibliographic Details
Main Authors: Sako, Hiroyuki, Fukuda, Kazumasa, Saikawa, Yoshiro, Nakamura, Rieko, Takahashi, Tsunehiro, Wada, Norihito, Kawakubo, Hirohumi, Takeuchi, Hiroya, Ohmori, Tai, Kitagawa, Yuko
Format: Online
Language:English
Published: Public Library of Science 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164645/